Woodford-backed biotech Prothena plunges as key drug fails

LONDON (Reuters) - Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial.

from Reuters: Health News https://ift.tt/2Hnmohr
via IFTTT